8-K: Utah Medical Products Reports Mixed Q1 2024 Results Amidst Sales Decline

Utah Medical Products experienced a decrease in revenue and profitability in the first quarter of 2024, despite some positive developments in cost management and non-operating income.

Summary

• Utah Medical Products reported a decrease in revenue of 9.4% in the first quarter of 2024 compared to the same period in 2023, with total sales at $11.34 million.
• Gross profit decreased by 13.7% to $6.766 million, and operating income fell by 12.5% to $3.883 million.
• Net income declined by 6.1% to $3.956 million, and earnings per share (EPS) decreased by 5.7% to $1.093.
• Domestic sales were down 14%, while international sales decreased by 3% in USD terms, or 4% in constant currency.
• The company's gross profit margin decreased from 62.6% to 59.7% due to manufacturing overhead costs not declining proportionally with sales.
• Operating expenses decreased due to the full amortization of a key intangible asset, but this was partially offset by increased litigation expenses.
• Non-operating income increased due to higher interest income on cash reserves, partially mitigating the decline in operating income.
• The company repurchased 43,108 shares at an average price of $69.37 per share during the quarter.
• Cash and investments increased to $93.8 million, despite $4.1 million being used for dividends and share repurchases.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the decline in key financial metrics, including revenue, gross profit, and net income. While there are some positives, such as increased non-operating income and share repurchases, the overall trend is concerning.

Positives

• Non-operating income increased due to higher interest income on cash reserves.
• The company's EBT margin improved to 42.3% from 40.9% in the same period last year.
• The company repurchased 43,108 shares, indicating management's belief in the company's value.
• The company's balance sheet remains strong with $93.8 million in cash and investments and a current ratio of 19.6.
• The decline in gross profit margin was less than expected due to a favorable product mix and improved direct labor productivity.
• Operating expenses decreased due to the full amortization of a key intangible asset.

Negatives

• Total revenue decreased by 9.4% compared to the same quarter last year.
• Gross profit decreased by 13.7% due to lower sales and reduced gross profit margin.
• Domestic sales decreased by 14%, with significant declines in OEM and Filshie device sales.
• Operating income decreased by 12.5% due to lower gross profit and increased litigation and R&D expenses.
• Net income decreased by 6.1% compared to the same quarter last year.
• The company experienced a decrease in sales of NICU devices due to supply chain disruptions.
• Filshie device sales were negatively impacted by misinformation on social media related to product liability lawsuits.

Risks

• The company faces risks related to global economic conditions, market acceptance of products, and regulatory approvals.
• Supply chain disruptions continue to impact the company's ability to recapture lost business in NICU devices.
• Misinformation on social media is negatively affecting sales of Filshie devices.
• The company expects revenues to decline further during the remainder of 2024, which will likely lead to a greater percentage decline in gross profit.
• Increased litigation expenses are impacting the company's profitability.

Future Outlook

Management believes that the Q1 2024 operating performance is consistent with achieving its financial performance projections for the calendar year 2024, as previously provided in its Year 2023 SEC 10-K Report. However, management expects revenues to decline further during the remainder of 2024, which will likely lead to a greater percentage decline in gross profit.

Management Comments

• Management believes that the 1Q 2024 operating performance provides a start that is consistent with achieving its financial performance projections for the calendar year 2024.
• Management expects revenues to decline further during the remainder of 2024, taken together with manufacturing overhead expenses not declining, management has projected a greater percentage decline in GP for the year as a whole.

Industry Context

The medical device industry is facing various challenges, including supply chain disruptions and increased competition. Utah Medical Products' results reflect these challenges, particularly in the areas of supply chain and product liability issues. The company's focus on specialty medical devices for women and babies positions it in a niche market, but it is still subject to broader industry trends.

Comparison to Industry Standards

• Comparing Utah Medical Products to similar medical device companies, such as those in the small to mid-cap range, reveals a mixed performance.
• Companies like ICU Medical and Merit Medical Systems, which also operate in the medical device space, have shown varying results in recent quarters, with some experiencing growth while others face similar challenges in supply chain and sales.
• UTMD's gross profit margin of 59.7% is within the range of industry averages, but the decline from 62.6% indicates potential issues with cost management.
• The company's strong cash position and current ratio are positive indicators compared to industry benchmarks, suggesting financial stability.
• However, the decline in sales and profitability is a concern, as many medical device companies are experiencing growth in the post-pandemic environment.

Stakeholder Impact

• Shareholders may be concerned about the decline in revenue and profitability, but may be encouraged by the share repurchases and strong cash position.
• Employees may be affected by potential cost-cutting measures if the company's financial performance does not improve.
• Customers may experience delays or disruptions due to supply chain issues.
• Suppliers may be impacted by changes in the company's production and purchasing activities.

Next Steps

• The company will continue to monitor and address supply chain disruptions.
• Management will focus on managing manufacturing overhead costs to improve gross profit margins.
• The company will continue to evaluate opportunities for share repurchases.
• The company will continue to monitor and address the impact of misinformation on social media on Filshie device sales.

Key Dates

Keywords

medical devices, financial results, revenue, profitability, sales, gross profit, operating income, net income, EPS, share repurchase, EBITDA, Utah Medical Products